Rick Heinick

Executive Chairman, TearClear

Solo VC collaborating with distinguished co-investors. Board member and strategic advisor to CEOs in pharmaceutical and medical device companies. Expertise in life science early-stage businesses and ophthalmology industry.

Founded and helped launch TearClear, serving as Executive Chairman. TearClear is transforming trusted ophthalmic drugs into best-in-class therapies.  Board member and helped fund the cardiology company UltraSight Medical (Israel) as well as Lentechs (Columbus, OH), TherOptix (Boston, MA), and board advisor to AI Optics (New York City, NY). In addition, have invested in dozens of other life science companies.

Served as executive and officer at Bausch + Lomb helping lead a turnaround of the business. Also was CEO and board member of RxSight/Calhoun Vision and Amydis Diagnostics.

Co-authored The Merger Dividend, published in the Harvard Business Review (July/Aug 2011). Bachelor’s degree from Boston University, and a Master of Management from McGill University.